Clinical trials
Small Cell Lung Cancer clinical trials
Below are recruiting small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 1,502 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07188480Recruiting
DNA and RNA testing for advanced lung cancer
This study tests a new way to analyze DNA and RNA from lung tumor samples taken during a bronchoscopy. It aims to find genetic changes that could help guide treatment for people with advanced non-small cell lung cancer.
Bologna, BolognaAges 18 years+ - NCT07087223RecruitingPhase 1/Phase 2
Study of vebreltinib plus furmonertinib for NSCLC with c-Met amplification
This trial tests a combination of two targeted therapies (vebreltinib and furmonertinib) for people with a specific type of advanced non-small cell lung cancer (NSCLC) that has a change called c-Met amplification and has stopped responding to earlier EGFR-targeted treatment. It aims to see if adding vebreltinib can help control the cancer.
Neimeng, NeimengAges 18 years+ - NCT07534033RecruitingPhase 2
Probiotic LR607 for newly diagnosed lung cancer
This study tests whether a probiotic supplement (LR607) can help patients with newly diagnosed non-small cell lung cancer—a common type of lung cancer. Probiotics are beneficial bacteria that may help your immune system fight cancer alongside standard treatments.
GuangzhouAges 18–80 - NCT07109401RecruitingPhase 2
Immunotherapy for early-stage small cell lung cancer that can be removed with surgery
This trial tests whether giving immunotherapy before and after surgery can help people with limited-stage small cell lung cancer. It is for patients whose cancer has not spread widely and can be completely removed by surgery.
ShanghaiAges 18–75 - NCT07113691RecruitingPhase 1
Experimental drug plus radiation and immunotherapy for lung cancer
This study tests a combination of three treatments for extensive-stage small cell lung cancer that has worsened after initial chemotherapy: an experimental pill, focused radiation (SBRT), and an immunotherapy drug. The goal is to see if this triple therapy can help the immune system fight the cancer more effectively.
New Haven, ConnecticutAges 18 years+ - NCT07058519RecruitingPhase 2
Personalized osimertinib treatment guided by blood test for EGFR lung cancer
This trial tests a personalized treatment plan for advanced lung cancer with an EGFR mutation. It uses a blood test (ctDNA) to guide treatment with osimertinib (a targeted pill) plus chemotherapy. The goal is to see if adjusting therapy based on the blood test results can help you live longer with fewer side effects.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07107490RecruitingPhase 1
Study of ALPS12 for advanced small cell lung cancer
This study tests a new drug called ALPS12 for people with extensive-stage small cell lung cancer that has come back after at least one prior treatment. It aims to see if the drug is safe and effective.
Hong KongAges 18 years+ - NCT05703971RecruitingPhase 1/Phase 2
Maintenance treatment with a gene therapy plus atezolizumab
This Phase 1/2 trial tests whether a gene therapy called Reqorsa given with atezolizumab can help people with extensive-stage small cell lung cancer (ES-SCLC) stay controlled after their first chemo. It may help by boosting the immune system to keep the cancer from growing again.
Lone Tree, ColoradoAges 18 years+ - NCT07169708Recruiting
Study of nivolumab and chemo before surgery for lung cancer
This trial looks at real-world outcomes in Taiwan for people with resectable non-small cell lung cancer (NSCLC) who get nivolumab combined with chemotherapy before surgery. It aims to understand how well this treatment works and how safe it is.
Kaohsiung CityAges 18 years+ - NCT07308106RecruitingPhase 2
Testing SKB571 for MET-mutated advanced lung cancer
This trial tests a new drug called SKB571 for people with advanced lung cancer that has a specific change in the MET gene. The goal is to see if the drug can shrink tumors or stop them from growing.
ShanghaiAges 18–75 - NCT06853678Recruiting
Immunotherapy after first treatment for extensive stage small cell lung cancer
This trial tests immunotherapy drugs for extensive stage small cell lung cancer that has progressed after initial (first-line) chemotherapy. You may be eligible if you have finished standard treatment and your cancer has worsened.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05150145Recruiting
Radiation versus observation for liver spread of small cell lung cancer
This trial compares giving liver-directed radiation to watching closely without radiation. It is for people with small cell lung cancer that has spread to the liver, to see whether radiation helps control the disease.
Guiyang, GuizhouAges 18–70 - NCT07459751RecruitingPhase 2/Phase 3
A study of HLX43 alone or with HLX07 vs docetaxel for advanced squamous lung cancer
This trial tests a new drug called HLX43, given alone or with HLX07, against the standard chemo docetaxel for people with a type of advanced lung cancer called squamous non-small cell lung cancer. It's for patients who have already tried and not responded to platinum chemo and immunotherapy.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07217301RecruitingPhase 3
Comparing TAK-928 to docetaxel for advanced lung cancer
This study tests a new drug called TAK-928 against the standard chemo docetaxel for people with advanced squamous non-small cell lung cancer. You may be able to join if you have already tried a checkpoint inhibitor and platinum chemotherapy, and your cancer has grown.
Jonesboro, ArkansasAges 18 years+ - NCT07227597RecruitingPhase 1/Phase 2
Study of two experimental drugs for advanced small cell lung cancer
This study tests two experimental drugs, gocatamig and ifinatamab deruxtecan, for people with advanced small cell lung cancer. The goal is to see if this combination can help control the cancer, either as a first treatment or after initial standard therapy.
Santa Rosa, CaliforniaAges 18 years+ - NCT07085182RecruitingPhase 2
Tislelizumab plus radiation for advanced lung cancer
This trial tests combining the immunotherapy drug tislelizumab with radiation therapy for people with advanced non-squamous non-small cell lung cancer that hasn't been treated before. It aims to see if this combination helps control the cancer better than standard treatments.
Zibo, ShandongAges 18–75 - NCT06735391RecruitingPhase 3
JMT101 plus osimertinib vs osimertinib for EGFR-mutant lung cancer
This trial tests a new combination of two targeted drugs (JMT101 and osimertinib) against osimertinib alone for people with advanced lung cancer that has an EGFR mutation. The goal is to see if the combination works better as a first treatment.
GuangzhouAges 18 years+ - NCT05800223RecruitingPhase 3
Armatinib with or without brain radiation for EGFR lung cancer
This study tests whether armatinib alone or combined with focused brain radiation (SRT) can control brain metastases from EGFR-mutated non-small cell lung cancer. It aims to improve outcomes for people with few, mostly low-symptom brain spots.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06631989RecruitingPhase 1/Phase 2
Study of WSD0922-FU for advanced EGFR-mutant lung cancer
This trial tests a new drug called WSD0922-FU for people with advanced non-small cell lung cancer that has a specific EGFR gene change. It aims to see if the drug can help when previous EGFR treatments have stopped working.
Hefei, AnhuiAges 18–75 - NCT07322783RecruitingPhase 2
Osimertinib plus savolitinib for resistant lung cancer
This trial tests a combination of two targeted drugs (osimertinib and savolitinib) for people with a specific type of advanced non-small cell lung cancer that has stopped responding to standard treatments. It may help patients whose cancer has a low number of MET gene copies.
QingdaoAges 18–80 - NCT07584239Recruiting
Physical therapy and relaxation before lung cancer surgery
This trial tests whether physical therapy exercises and relaxation techniques done before surgery can help adults with lung cancer feel stronger, recover better, and have better surgical outcomes. You'll work with specialists to prepare your body and mind for the operation.
Columbus, OhioAges 18 years+ - NCT06429696RecruitingPhase 2
Maintenance therapy for extensive stage small cell lung cancer
This study tests if a combination of an immunotherapy drug (PD-L1 inhibitor) and a targeted therapy pill (apatinib) can help keep extensive stage small cell lung cancer from growing after initial treatment. It is for people whose cancer was controlled with first-line chemo-immunotherapy.
Guangzhou, GuangdongAges 18–75 - NCT06430437RecruitingPhase 3
Study of SHR-A1811 for first-line treatment of advanced lung cancer with HER2 mutations
This trial tests a new drug called SHR-A1811 for people with advanced or metastatic non-small cell lung cancer that has a change (mutation) in the HER2 gene. You cannot have had any previous treatment for advanced lung cancer, and the cancer must be measurable outside the brain.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06008730RecruitingPhase 2
Proton beam radiation after lung cancer surgery
This trial tests if proton beam radiation therapy is safe and effective after surgery for non-small cell lung cancer that has spread to lymph nodes in the chest. It is for people who have already had chemotherapy before their surgery.
Atlanta, GeorgiaAges 18 years+
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for small cell lung cancer?
- Yes. Clin2 currently lists 1,502 recruiting small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Beyond the search
We also like to point to nonprofits doing real good in this area. We aren’t affiliated with them — we just admire the work.
- Stand Up To CancerPeople facing cancer across many types, through the research that leads to better treatments.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.